Table of Contents

1.0  Introduction

(Revised 8/13)

2.0  Map - Districts for Statewide Disease Investigation/Terrorism Response/TB Control

(Updated 7/19)

3.0  Communicable Disease Surveillance

(Updated 12/14)

4.0  Diseases or Conditions

    Anaplasmosis

(4/08)

    Animal Bites / Injuries

(7/03)

    Anthrax

(Revised 2/11)

    Arboviral Diseases, Neuroinvasive and Non-Neuroinvasive

(Revised 4/15)

        California Serogroup Viruses, including La Crosse Virus

        Chikungunya Virus

        Eastern Equine Encephalitis Virus

        Powassan Virus

        St. Louis Encephalitis Virus

        Venezuelan Equine Encephalitis Virus

        West Nile

        Western Equine Encephalitis

    Babesiosis

(New 5/16)

    Botulism

(Revised 12/13)

    Brucellosis

(Revised 10/13)

    Campylobacteriosis

(Updated 10/23)

    Chancroid

Under construction

    Chlamydia Trachomatis

Under construction

    Cholera

(Updated 4/12)

    Coccidioidomycosis

(Revised 1/12)

    Creutzfeldt-Jakob Disease

(Revised 5/16)

    Cryptosporidiosis

(Revised 8/11)

    Cyclosporiasis

(Revised 10/11)

    Dengue

(Revised 1/15)

    Diphtheria

(Updated 3/12)

    Escherichia coli O157:H7/Other Hemorrhagic E. coli

(Revised 6/11)

    Ehrlichiosis

(Revised 4/08)

    Giardiasis

(Revised 2/14)

    Glanders

(Updated 3/12)

    Gonorrhea

Under construction

    Haemophilus influenzae, Invasive

(Revised 1/15)

    Hansen's Disease (Leprosy)

(Revised 4/12)

    Hantavirus Infections

(Revised 6/15)

    Hemolytic Uremic Syndrome (HUS), post-diarrheal

(Updated 6/24)

    Hemorrhagic Fevers (Viral)

(Updated 11/15)

         Arenaviridae: South American Hemorrhagic Viral Fevers (New World Arenaviruses)

         Arenaviridae: Lassa Fever (Old World Arenavirus)

         Bunyaviridae: Crimean-Congo Hemorrhagic Fever

         Filoviridae: Ebola Hemorrhagic Fever

         Filoviridae: Marburg Hemorrhagic Fever

    Hepatitis A

(Updated 6/23)

    Hepatitis B

Under construction

    Hepatitis C

Under construction

    HIV/AIDS

Under construction

    Influenza

(Updated 6/17)

    Latent Tuberculosis Infection

(Revised 3/14)

    Legionellosis

(Revised 2/24)

    Leptospirosis

(Updated 11/15)

    Listeriosis

(Updated 1/14)

    Lyme-like Disease

(Revised 5/08)

    Malaria

(Revised 3/14)

    Measles

(Updated 6/24)

    Meningococcal Disease

(Updated 7/23)

    Methicillin–resistant Staphylococcus aureus (MRSA)

(5/11)

    Mumps

(Revised 8/13)

    Nontuberculous Mycobacterium (NTM) / MOTT

(Revised 1/15)

    Outbreak Investigation

(Updated 6/24)

    Other Sexually Transmitted Diseases

Under construction

          Nongonococcal Urethritis

          Mucopurulent Cervicitis

          Bacterial Vaginosis

          Trichomonal Vaginosis

          Vulvovaginal Candidiasis

          Genital Herpes

          Lymphogranuloma Venereum

          Molluscum Contagiousum

          Pelvic Inflammatory Disease (PID)

          Urinary Tract Infection

          Human Papillomavirus

          Acute Epididymitis

    Paragonimiasis

(2/11)

    Perinatal Hepatitis B Case Management Form - PHB 29

    Pertussis

(Updated 8/23)

    Plague

(Revised 9/12)

    Polio

(Updated 5/12)

    Psittacosis

(Revised 1/16)

    Q fever

(Revised 5/15)

    Rabies

 

          Rabies, animal

(Revised 1/14)

          Rabies, human

(Revised 1/14)

    Ricin

(Updated 2/13)

    Rocky Mountain Spotted Fever/Spotted Fever Rickettsioses

(Revised 2/20)

    Rubella

(Revised 11/13)

    Salmonellosis, Nontyphoidal (NTS)

(Revised 6/17)

    Shiga toxin-producing E. coli (STEC) and
    Shiga toxin positive, unknown organism

(Revised 6/11)

    Shigellosis

(Updated 9/23)

    Smallpox

(Revised 11/13)

    Streptococcus pneumoniae, Invasive Pneumococcal Disease (IPD)

(New 6/17)

    Streptococcal Toxic Shock Syndrome

(Revised 2/16)

    Syphilis

Under construction

    T-2 Mycotoxicosis

Revised (5/16)

    Tetanus

(Revised 11/13)

    Toxic Shock Syndrome, Non-Streptococcal

(Revised 5/16)

    Trichinellosis

(Revised 4/15)

    Tuberculosis Disease

(Revised 3/12)

    Tularemia

(Revised 4/16)

    Typhoid & Paratyphoid Fever

(Revised 7/15)

    Vaccinia, Adverse Reactions

(Revised 4/05)

    Vancomycin-Intermediate Staphylococcus aureus (VISA) and     Vancomycin-Resistant Staphylococcus aureus (VRSA)

(5/11)

    Varicella (Chickenpox)

(Revised 5/11)

    Vibriosis (non-cholera Vibrio species infections)

(11/12)

    Yellow Fever

(Updated 10/15)

    Yersiniosis

(Revised 3/12)

    Appendices

(Revised 9/10)



Key

New

Recently added manual section.

Reviewed

Section content is current.

Revised

Section content:  may include reporting guidelines, forms, and intervention recommendations.

Updated

Web links, agency names and phone numbers.